Jiang Z, Sun W, Du R, Yang R
Clin Transl Oncol. 2024; 26(9):2116-2125.
PMID: 38558284
DOI: 10.1007/s12094-024-03451-2.
Paller C, Huang E, Luechtefeld T, Massett H, Williams C, Zhao J
Front Med (Lausanne). 2019; 6:122.
PMID: 31214592
PMC: 6558040.
DOI: 10.3389/fmed.2019.00122.
Chiuzan C, Shtaynberger J, Manji G, Duong J, Schwartz G, Ivanova A
J Biopharm Stat. 2017; 27(3):477-494.
PMID: 28166468
PMC: 5383533.
DOI: 10.1080/10543406.2017.1289952.
Awasthi S, Wilken R, Patel F, German J, Mills D, Lebrilla C
Trials. 2016; 17(1):340.
PMID: 27449926
PMC: 4957407.
DOI: 10.1186/s13063-016-1467-1.
Wong K, Capasso A, Eckhardt S
Nat Rev Clin Oncol. 2015; 13(2):106-17.
PMID: 26552953
DOI: 10.1038/nrclinonc.2015.194.
Clinical trials: Early phase clinical trials-are dose expansion cohorts needed?.
Iasonos A, OQuigley J
Nat Rev Clin Oncol. 2015; 12(11):626-8.
PMID: 26441082
PMC: 4758199.
DOI: 10.1038/nrclinonc.2015.174.
Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.
Sharan S, Woo S
Front Pharmacol. 2015; 6:33.
PMID: 25750626
PMC: 4335258.
DOI: 10.3389/fphar.2015.00033.
A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.
Wages N, Slingluff Jr C, Petroni G
Contemp Clin Trials. 2015; 41:172-9.
PMID: 25638752
PMC: 4380742.
DOI: 10.1016/j.cct.2015.01.016.
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.
Chalret du Rieu Q, Fouliard S, White-Koning M, Kloos I, Chatelut E, Chenel M
Invest New Drugs. 2014; 32(5):985-94.
PMID: 24875134
DOI: 10.1007/s10637-014-0118-1.
Modeling NSCLC progression: recent advances and opportunities available.
Suleiman A, Nogova L, Fuhr U
AAPS J. 2013; 15(2):542-50.
PMID: 23404126
PMC: 3675755.
DOI: 10.1208/s12248-013-9461-y.
Bevacizumab in ovarian cancer: unanswered questions.
Muggia F
Drugs. 2012; 72(7):931-6.
PMID: 22564133
DOI: 10.2165/11633510-000000000-00000.
Envisioning the future of early anticancer drug development.
Yap T, Sandhu S, Workman P, de Bono J
Nat Rev Cancer. 2010; 10(7):514-23.
PMID: 20535131
DOI: 10.1038/nrc2870.
Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.
Le Tourneau C, Dieras V, Tresca P, Cacheux W, Paoletti X
Target Oncol. 2010; 5(1):65-72.
PMID: 20361265
DOI: 10.1007/s11523-010-0137-6.
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules.
Grothey A, Galanis E
Nat Rev Clin Oncol. 2009; 6(9):507-18.
PMID: 19636328
DOI: 10.1038/nrclinonc.2009.110.
Dose escalation methods in phase I cancer clinical trials.
Le Tourneau C, Lee J, Siu L
J Natl Cancer Inst. 2009; 101(10):708-20.
PMID: 19436029
PMC: 2684552.
DOI: 10.1093/jnci/djp079.
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?.
Postel-Vinay S, Arkenau H, Olmos D, Ang J, Barriuso J, Ashley S
Br J Cancer. 2009; 100(9):1373-8.
PMID: 19401696
PMC: 2694416.
DOI: 10.1038/sj.bjc.6605030.
